PMID- 37604307
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20231217
IS  - 2156-5376 (Electronic)
IS  - 2161-8313 (Print)
IS  - 2161-8313 (Linking)
VI  - 14
IP  - 6
DP  - 2023 Nov
TI  - The Effect of Zinc Supplementation on Lipid Profiles in Patients with Type 2 
      Diabetes Mellitus: A Systematic Review and Dose-Response Meta-Analysis of 
      Randomized Clinical Trials.
PG  - 1374-1388
LID - S2161-8313(23)01356-X [pii]
LID - 10.1016/j.advnut.2023.08.006 [doi]
AB  - Research on the effects of zinc supplementation on lipid profiles in people with 
      type 2 diabetes mellitus (T2DM) has been inconsistent. This systematic review and 
      meta-analysis was performed to summarize the current data on the effects of zinc 
      supplementation on lipid profiles in patients with T2DM. Three online databases 
      including PubMed, Scopus, and Web of Science were searched to find relevant 
      studies published until September 2022. The exposure was zinc supplementation, 
      and the outcomes were low-density lipoprotein (LDL), high-density lipoprotein 
      (HDL), triglyceride (TG), and total cholesterol (TC). Fourteen randomized 
      clinical trials consisting of 1067 patients were included in the statistical 
      analysis. Significant improvement was observed in all 4 lipid profile components. 
      Following zinc supplementation, a significant decrease was observed in TC 
      (weighted mean difference [WMD]: -16.16; 95% confidence interval [CI]: -26.43, 
      -5.89; P = 0.002), LDL (WMD: -6.18; 95% CI: -9.35, -3.02; P < 0.001), and TG 
      (WMD: -13.08; 95% CI: -21.83, -4.34; P = 0.003). After analyzing 13 studies 
      reporting HDL, a significant increase was seen (WMD: 3.76; 95% CI: 1.30, 6.22; P 
      = 0.003). In a nonlinear dose-response analysis, a significant inverse 
      association was observed between <12 wk zinc supplementation and TC, LDL, and TG 
      (TC: WMD: -5, P(nonlinearity) < 0.001; LDL: WMD: -5, P(nonlinearity) = 0.07, TG: 
      WMD: -16.5, P(nonlinearity) = 0.006). Nonlinear dose-response analysis shows that 
      the optimum elemental zinc dosage for the best response to the supplementation 
      for TC, LDL, and TG are 120, 100, and 140 mg/d, respectively (TC: WMD: -5, 
      P(nonlinearity) < 0.001; LDL: WMD: -10, P(nonlinearity) = 0.006, TG: WMD: -50, 
      P(nonlinearity) = 0.031). In conclusion, we found significant changes in all 4 
      components of the lipid profile through zinc supplementation in T2DM patients. 
      Based on our findings, zinc supplementation may have profound favorable 
      consequences on the lipid profile of T2DM patients, especially in the 
      zinc-deficient group.
CI  - Copyright (c) 2023 The Author(s). Published by Elsevier Inc. All rights reserved.
FAU - Heidari Seyedmahalleh, Mohammad
AU  - Heidari Seyedmahalleh M
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Montazer, Mohsen
AU  - Montazer M
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences, Tehran, Iran.
FAU - Ebrahimpour-Koujan, Soraiya
AU  - Ebrahimpour-Koujan S
AD  - Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences, Tehran, Iran; Autoimmune Bullous Disease 
      Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, 
      Iran.
FAU - Azadbakht, Leila
AU  - Azadbakht L
AD  - Department of Community Nutrition, School of Nutritional Sciences and Dietetics, 
      Tehran University of Medical Sciences, Tehran, Iran; Diabetes Research Center, 
      Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of 
      Medical Sciences, Tehran, Iran; Department of Community Nutrition, School of 
      Nutrition and Food Science, Isfahan University of Medical Sciences, Isfahan, 
      Iran. Electronic address: azadbakhtleila@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20230819
PL  - United States
TA  - Adv Nutr
JT  - Advances in nutrition (Bethesda, Md.)
JID - 101540874
RN  - J41CSQ7QDS (Zinc)
RN  - 0 (Triglycerides)
SB  - IM
MH  - Humans
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - Dietary Supplements/adverse effects
MH  - Zinc/pharmacology
MH  - Randomized Controlled Trials as Topic
MH  - Triglycerides
PMC - PMC10721485
OTO - NOTNLM
OT  - lipid profile
OT  - meta-analysis
OT  - type-2 diabetes mellitus
OT  - zinc
EDAT- 2023/08/22 00:42
MHDA- 2023/12/01 06:44
PMCR- 2023/08/19
CRDT- 2023/08/21 19:26
PHST- 2023/02/17 00:00 [received]
PHST- 2023/07/20 00:00 [revised]
PHST- 2023/08/15 00:00 [accepted]
PHST- 2023/12/01 06:44 [medline]
PHST- 2023/08/22 00:42 [pubmed]
PHST- 2023/08/21 19:26 [entrez]
PHST- 2023/08/19 00:00 [pmc-release]
AID - S2161-8313(23)01356-X [pii]
AID - 10.1016/j.advnut.2023.08.006 [doi]
PST - ppublish
SO  - Adv Nutr. 2023 Nov;14(6):1374-1388. doi: 10.1016/j.advnut.2023.08.006. Epub 2023 
      Aug 19.